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Abstract
Wnt7a is known to be a tumor suppressor that is lost in NSCLC, but no mechanism of loss has been established. Methylation
of promoter regions has been established as a common mechanism of loss of tumor suppressor expression in NSCLC. We
previously demonstrated that loss of Wnt7a in non-transformed lung epithelial cell lines led to increased cell growth, altered
3-D culture growth, and increased migration. The Wnt7a promoter has a higher percentage of methylation in NSCLC tumor
tissue compared to matched normal lung tissue and methylation of the promoter region leads to decreased activity. We
treated H157 and H1299 NSCLC cell lines with 5-Aza-29-deoxycytidine and detected loss of Wnt7a promoter methylation,
increased Wnt7a expression, and increased activity of the Wnt7a lung signaling pathway. When DNMT1 expression was
knocked down by shRNA, expression of Wnt7a increased and methylation decreased. Together these data suggest that in
NSCLC, Wnt7a is lost by methylation in a subset of tumors and that this methylation is maintained by DNMT1. Restoration of
Wnt7a expression through demethylation could be an important therapeutic approach in the treatment of NSCLC.
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Introduction
Lung cancer continues to be the leading cause of cancer death,
with minimal options available for treatment of tumors typically
diagnosed at late stages. We are interested in the role of non-
canonical Wnt signaling in non-small lung cancer (NSCLC),
specifically the tumor suppressive activities of Wnt7a and its
receptor Frizzled 9 (Fzd9). Wnt7a is highly expressed in embryonic
lung and serves to maintain a normal epithelial phenotype in the
adult lung [1,2]. Previous studies have demonstrated that Wnt7a is
frequently lost in NSCLC and that restoration of Wnt7a
expression leads to decreased transformed growth in NSCLC cell
lines [2]. NSCLC cells with reexpression of Wnt7a have decreased
proliferation, decreased anchorage independent growth, and
restoration of an epithelial phenotype [2]. Wnt7a is located on
chromosome 3p25, which is a ‘‘hotspot’’ for deletion, however, we
suspected that Wnt7a expression in NSCLC can be regulated by
an epigenetic mechanism [3].
Methylation of tumor suppressor gene promoters in NSCLC
has been reported in over 40 genes, some with frequencies as high
as 100% [4]. Loss of expression of genes such as p16/INK4a by
methylation early in the development of NSCLC has been
proposed as a biomarker for early detection [5]. Methylation of
genes such as FHIT have been correlated with tumor staging and
prognosis in NSCLC [6]. Differences in methylation associated
with tumor histology have been identified for genes such as
RASSF1A and p16/INK4a [7,8]. Associations between exposure
to cigarette smoke and aberrant methylation have been observed
for p16, RASSF1A, and RARb2 among others [9,10,11]. A link
between exposure to tobacco carcinogens and methylation may
exist through DNA Methyltransferases (DNMT) that are activated
by these carcinogens. If targets of DNMTs responsible for DNA
repair become inappropriately inactivated by methylation, lesions
resulting from carcinogens may persist, leading to tumorigenesis
[12].
As most Wnt and Wnt-related protein studies in cancer are
related to canonical signaling, the identification of Wnt-specific
methylation is not common. Methylation is known to be a
mechanism of loss for other tumor suppressors in NSCLC, but
most studies of Wnt methylation in the lung target Wnt antagonists
in the canonical Wnt signaling pathway. A few studies have
identified hypermethylation of Wnt5a and Wnt9a in epithelial
cancers and hypermethylation of Wnt7a has been observed in a
subset of ductal pancreatic cancer [13,14,15,16]. In the present
study, we have demonstrated that loss of Wnt7a is a significant
event for lung epithelial cells and that this loss is caused by
methylation through DNMT1 activity in a subset of NSCLC.
Results
Loss of Wnt7a expression in lung cells leads to a
transformed phenotype
We have previously demonstrated that Wnt7a expression alters
the transformed characteristics of NSCLC cells. NSCLC cells with
reintroduced Wnt7a have decreased proliferation, decreased
anchorage independent growth, and restoration of an epithelial
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32921phenotype. The converse, loss of Wnt7a from a non-transformed
epithelial cell, would be expected to result in an increase in the
characteristics of transformed cells. In this study, we used an
shRNA approach to knock down mRNA expression of Wnt7a in
two non-transformed lung epithelial cell lines, HBEC and Beas2B
(B2B), and confirmed knock down by QPCR and western blot
(Fig. 1A). Decreased Wnt7a expression led to increased cell
proliferation in B2B cells, demonstrated by a 6-day cell growth
assay (Fig. 1B). HBEC cell proliferation was also increased with
loss of Wnt7a as measured by MTS assay (data not shown). In B2B
cells, altered growth in Matrigel 3D culture was observed at 5 days
with loss of Wnt7a expression (Fig. 1C). Increased cell migration in
a scratch assay at 24 hours was observed with loss of Wnt7a
expression, where arrows indicated the edges of the introduced
scratch (Fig. 1C).
Wnt7a is methylated in human NSCLC cell lines and
tissues
The question of how Wnt7a expression is lost could be
addressed in several ways. Wnt7a could be deleted, mutated, or
methylated, among other mechanisms. While the chromosome
containing Wnt7a (3p25) is frequently deleted in NSCLC, this
mechanism of loss, along with gene mutation, currently offers little
in the way of therapeutic intervention [17]. The presence of the
Figure 1. Effects of Wnt7a loss in lung epithelial cells. A) Expression of Wnt7a was measured by QPCR in HBEC and B2B cells after stable
transfection with Wnt7a shRNA or a negative shRNA. Data is presented as fold-change in Wnt7a expression normalized to GAPDH. Error bars are the
SE of triplicate experiments. Wnt7a knock down was also confirmed by western blot with a b-actin loading control. B) Cell proliferation was measured
in B2B cells expressing Wnt7a shRNA or a negative shRNA. Cells were analyzed in a 6-day growth assay. C) B2B cells with Wnt7a shRNA were analyzed
in a 3D culture assay using Matrigel and observed after 5 days of growth for changes in morphology compared to a negative shRNA control. B2B cells
with Wnt7a shRNA were also analyzed in a scratch migration assay and observed at 24 hours for movement into the introduced scratch compared to
a negative shRNA control. Arrows indicate edges of the scratch. Pictures represent triplicate experiments.
doi:10.1371/journal.pone.0032921.g001
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using current clinical interventions to treat NSCLC. We treated
HBEC and B2B cells with tobacco carcinogen NNK, which is
known to lead to accumulation of DNMT1 and increased tumor
suppressor hypermethylation in NSCLC [18]. In the treated cells
we observed a decrease in Wnt7a mRNA expression by QPCR
compared to untreated cells (Fig. 2A). Methylation analysis
demonstrated that the Wnt7a promoter in B2B and HBEC cells
has increased methylation after exposure to 10 uM NNK
(Figure 2A). This suggested that Wnt7a is methylated with
exposure to tobacco and may be a mechanism of loss in
tobacco-associated NSCLC. In order to determine whether
methylation of Wnt7a was present in human lung tumor tissue,
we measured methylation of a CpG island in the promoter in 82
pairs of human lung tumor tissue and matched normal lung tissue.
Mean percent methylation of the 13 CpG sites measured was
significantly higher in tumor tissue compared to normal tissue
when analyzed by a paired t-test (Fig. 2B). Table S1 shows percent
methylation at each CpG site analyzed and compared between
tumor and normal tissues. No single CpG site analyzed can be
identified as critical to inactivation of the Wnt7a promoter,
however, there appears to be a trend toward increased
methylation in tumors at CpG sites closer to the transcription
start site. Two cell NSCLC cell lines, H157 and H1299, were
identified as harboring Wnt7a promoter methylation by pyrose-
quencing and were used for subsequent in vitro experiments
Figure 2. Wnt7a is methylated in NSCLC cell lines and tissues. A) B2B and HBEC cells were treated with 10 uM NNK for 2 hours and Wnt7a
expression was measured by QPCR compared to an untreated control. Error bars are the SEM of triplicate experiments. Percent methylation in B2B
and HBEC cells was analyzed using the Methyl Profiler system after 2 hr 10 uM NNK treatment compared to untreated cells. B) Mean percent
methylation of the Wnt7a promoter was measured by pyrosequencing in NSCLC tissue and compared to matched normal adjacent lung tissue by
paired t-test. Mean percent methylation of B2B, H157, and H1299 cell lines was measured by pyrosequencing. C) A Wnt7a promoter luciferase was
modified by SssI, HpaII, and HhaI methylating enzymes and transiently transfected into B2B and HBEC cell lines. Fold-change in luciferase activity was
measured compared to unmodified Wnt7a promoter luciferase activity. Error bars are the SE of triplicate experiments.
doi:10.1371/journal.pone.0032921.g002
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methylation occurs in a subset of NSCLC.
The Wnt7a promoter deactivated by methylation is
restored with 5-aza-29 deoxycytidine treatment
As methylation of Wnt7a had not been studied previously, we
wanted to verify that methylation of the promoter region would
lead to inactivation of the promoter. A Wnt7a promoter luciferase
was treated with SssI, HpaII, and HhaI methylases to determine
the effect of methylation on the Wnt7a promoter region. SssI
affects all CpG sites, HpaII only the CpG within 50CCGG, and
HhaI only the CpG within 59GCGC. Transfection of the Wnt7a
promoter luciferase into B2B and HBEC cell lines demonstrated
decreased luciferase activity after treatment with all three
methylases compared to an untreated Wnt7a promoter luciferase,
indicating that even limited methylation inactivates the Wnt7a
promoter (Fig. 2C). We had identified two NSCLC cell lines with
methylation of the Wnt7a promoter region, H157 and H1299, and
wanted to determine the effect of treatment with a demethylating
agent, 5-aza-29 deoxycytidine (5 Aza). Cells were treated with
6 uM 5 Aza for 1–4 hours and expression of Wnt7a was measured
by QPCR and western blot. Exposure to 5 Aza led to increased
expression of Wnt7a mRNA and protein (Fig. 3A and B). As
expected, 5 Aza also led to decreased methylation of the Wnt7a
promoter region (Fig. 3D). Wnt7a is known to signal through its
receptor Fzd9 to downstream target PPARc, so we treated H157
and H1299 cells with 5 Aza, along with transient transfection of
Fzd9, and analyzed the activity of the Wnt7a signaling pathway
[19]. The PPAR response element luciferase (PPRE), which is
activated by PAPRc, demonstrated increased activity after cells
with methylated Wnt7a were exposed to 5 Aza and expression of
Fzd9 (Fig. 3C). These data indicate that pharmaceutical treatment
Figure 3. Treatment with 5 Aza reduces Wnt7a methylation. A) 157 and 1299 cells were treated with 5 Aza for 2 hours and Wnt7a was
measured by QPCR compared to untreated controls. Error bars are the SEM of triplicate experiments. B) 157 and 1299 cells were treated with 5 Aza
for 1, 2, and 4 hours and compared to untreated cells. Wnt7a protein expression was measured by immunoblot with b-actin as a loading control. C)
157 and 1299 cells were transiently transfected with Fzd9 and PPRE luciferase and 48 hours after were treated with 5 Aza for 2 hours. Luciferase
activity was measured and treated cells were compared to an empty control. Error bars are the SE of triplicate experiments. D) 1299 cells were treated
with 5 Aza for 2 hours and percent methylation of the Wnt7a promoter was measured by the Methyl-Profiler system. Treated cells were compared to
an untreated control. Error bar is the SE of triplicate experiments.
doi:10.1371/journal.pone.0032921.g003
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promoter.
Wnt7a promoter methylation is modulated by DNMT1
DNA methyltransferases (DNMT) modulate DNA methylation
and their overexpression has been associated with lung cancer [4].
DNMT1 is known to accumulate in the nucleus of NSCLC cells in
response to exposure to tobacco carcinogen NNK; we found that
exposure to NNK decreased expression of Wnt7a mRNA measured
by QPCR (Fig. 2A) [18]. When we knocked down expression of
DNMT1 in Wnt7A methylated cell lines H157 and H1299 using
shRNA, expression of DNMT1 decreased and expression of Wnt7a
correspondingly increased by QPCR (Fig. 4A). Decreased DNMT1
protein expression and increased Wnt7a expression was also
observed in H1299 cells (Fig. 4A). As expected, methylation of
Wnt7a in the DNMT1 knock down H1299 cells decreased when
measured by pyrosequencing (Fig. 4B). Similar to a study by Kassis
et al. that found decreased proliferation with RNAi depletion of
DNMT1, we observed a decrease in clonogenicity in H1299 cells
with knock down of DNMT1 compared to empty and negative
shRNA transfections (Fig. 4C). We also observed a return to the
clonogenicity of the empty transfection with the addition of Wnt7a
shRNA to the DNMT1 shRNA treated cells. This decreased
clonogenicity observed with DNMT1 shRNA treatment mimics
decreases in proliferation observed with restoration of Wnt7a
expression in previous studies [2]. This, combined with the
increased clonogenicity observed with the addition of Wnt7a
shRNA, suggests that loss of Wnt7a expression could be in part
responsible for the negative effects associated with DNMT1
overexpression in NSCLC [20]. Knock down of DNMT3a or 3b
in the H1299 cells did not result in increased Wnt7a expression,
suggesting that DNMT1 is responsible for de novo and maintenance
methylation of the Wnt7a promoter (Figure S1).
Cigarette smoke condensate exposure leads to Wnt7a
promoter methylation
Methylation has been shown to be increased with exposure to
tobacco carcinogens, so we were interested in the effect of cigarette
smoke condensate (CSC) on methylation of the Wnt7a promoter
[20]. We grew the non-transformed cell lines HBEC and B2B in
1% CSC media for 12 weeks and then extracted RNA, DNA, and
protein. QPCR analysis found decreased expression of Wnt7a in
both cell lines after 12 weeks of exposure to CSC (Fig. 5A).
Increased DNMT1 protein expression was confirmed in B2B cells
with CSC exposure (Fig. 5B). As expected, increased methylation
of the Wnt7a promoter region was also identified in both cell lines
(Fig. 5C). The exposure of lung epithelium to the carcinogens in
cigarette smoke is associated with increased methylation and
subsequent decreased expression of Wnt7a.
Discussion
The data from this study support the role of Wnt7a as a tumor
suppressor in lung epithelial cells and emphasize the role of Wnt7a
in maintaining an epithelial phenotype in adult lung tissue. Wnt7a
appears to be unique in the literature to date, as no other Wnt has
been identified in NSCLC as a tumor suppressor or as relevant to
the maintenance of a lung epithelial phenotype. Wnt5a is known
to antagonize b-catenin signaling in esophageal cancer, but in
NSCLC expression of Wnt5a appears to increase proliferation
[13,21,22]. The significantly adverse effect of the loss of Wnt7a on
lung epithelial cells motivated our determination of a mechanism
of loss. Also important is the potential to address therapeutic
strategies employing reexpression of Wnt7a.
Frequent loss of Wnt7a in NSCLC has been previously described
and in the current study, we presented data supporting the
importance of the expression of Wnt7a to the lung epithelium [2].
When Wnt7a expression is lost from non-transformed lung epithelial
cell lines, the cells acquire characteristics of transformed cells and
begin to more resemble NSCLC cell lines in proliferation rate, 3D
culture growth, and migration. If this loss of Wnt7a were to occur in a
human patient in combination with increased activity of oncogenes,
the effects could lead to development of a lung tumor that has
undergone EMT, which is associated with worse prognosis [23].
DNMT1 is thought to be responsible for maintaining
methylation patterns and its elevated expression has been
identified as a prognostic factor in NSCLC progression [24]. We
found that when DNMT1 expression is reduced, Wnt7a
methylation is reduced and expression increases. We have also
shown that Wnt7a is responsible for a part of the decreased cell
growth observed with DNMT1 loss. Typically, an additional
DNMT is involved in specific de novo gene promoter methylation,
while DNMT1 maintains this methylation. However, recent
studies have reported that DNMT1 also has de novo methyltrans-
ferase activity in CpG regions [12]. Our finding that loss of
DNMT3a or 3b expression does not result in increased Wnt7a
expression in H1299 cells suggests that DNMT1 may be the sole
DNMT responsible for promoter methylation of Wnt7a. If so, this
may make therapeutic demethylation of Wnt7a through reduction
of DNMT activity less complicated as only one DNMT would
have to be targeted and monitored.
Exposure to tobacco carcinogens in vitro and in vivo has been
associated with changes in DNMT activity and epigenetic
alterations [11,18,25,26]. In our study, treatment of non-
transformed lung epithelial cells with CSC led to increased
methylation of Wnt7a and a corresponding decrease in expression.
A previous study by Liu et al. found decreased Wnt7a expression
by array after CSC exposure [11]. Several studies have
demonstrated increased DNMT1 protein expression or accumu-
lation and increased methylation of specific genes after exposure to
tobacco carcinogens [18,25,26]. Loss of Wnt7a expression has
been identified as a frequent event in NSCLC, but this study is the
first to suggest a mechanism of loss and to show that tobacco
carcinogens may influence this loss [2].
Wnt7a plays a significant role in the maintenance of a normal
epithelial phenotype in lung tissue. As such, the loss of Wnt7a
could have a major impact on the development of lung cancer,
especially when combined with the upregulation of an influential
oncogene. This study investigates the important issue of how
Wnt7a expression is lost and how its expression can be restored in
an effort to treat lung cancer. Restoration of Wnt7a expression
may also have potential application in other epithelial cancers or
lung diseases. Therapeutic restoration of Wnt7a signaling in
NSCLC could be achieved with agents that are already in clinical
use, including demethylating agents and the prostacyclin analog
Iloprost, which we recently identified as an activator of the Wnt7a
signaling pathway [27]. Further work will be done to establish the
timing of Wnt7a loss and the potential in vivo effects of treatment
for Wnt7a methylation. The data from this study present a
significant and previously undescribed step toward the develop-
ment of therapeutic Wnt7a strategies for NSCLC.
Methods
Cell Culture, Human Tissue, and Reagents
NSCLC and Beas2B cell lines were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum at 37uCi na
humidified 5% CO2 incubator. The HBEC (human bronchial
Wnt7a Methylated in NSCLC
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Media at 37uC in a humidified 5% CO2 incubator. Cell lines were
obtained from ATCC (www.atcc.org), except the HBEC cell line,
which was obtained in 2009 from Dr. Robert Doebele at the
University of Colorado Denver [28]. Morphology of all cells lines
was monitored twice weekly and stocks of cell lines were passaged
Figure 4. DNMT1 modulates Wnt7a promoter methylation. A) 1299 cells were transiently transfected with DNMT1 shRNA and compared to
empty and shRNA negative control-transfected cells. DNMT1 and Wnt7a mRNA expression was measured by QPCR and presented as fold-change
compared to the empty control. Error bars are the SE of triplicate experiments. DNMT1 shRNA and a shRNA negative control were stably transfected
into 1299 cells and DNMT1 and Wnt7a protein were measured by immnoblot with a b-actin loading control. B) Transiently transfected 1299 cells were
analyzed for Wnt7a promoter methylation using pyrosequencing. DNMT1 shRNA and a negative shrNA control transfected cells were compared to
empty cells. Error bars are the SE of triplicate experiments. C) 1299 cells with transient DNMT1 shRNA and/or Wnt7a shRNA expression were
compared to an empty control and negative shRNA control in a clonogenicity assay. Cells were stained after 4 days of growth, photographed, and
counted for cloning efficiency. Error bars are the SE of duplicate experiments.
doi:10.1371/journal.pone.0032921.g004
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from 82 pairs of human lung tissue and adjacent normal lung
tissue were obtained from the University of Colorado Cancer
Center SPORE in Lung Cancer Pathology Core. NNK (Sigma)
was applied at 10 uM for 2 hours in cell growth media. Cells were
treated with 5-aza-29-deoxycytidine (5 Aza) (Sigma) at 6 uM in
cell growth media for 1–4 hours depending on the assay. Cigarette
smoke condensate (CSC) (Murty Pharmaceuticals) was applied at a
constant 1% concentration in the cell growth media for the 12
weeks.
Knockdown studies, proliferation, 3D culture, and scratch
assay
Wnt7a expression was knocked down stably in HBEC and B2B
cell lines using a lentiviral shRNA system from Open Biosystems
with puromycin selection. Dnmt expression was knocked down
using Sure-Silencing shRNA from SABiosciences with hygromycin
selection for stable expression. Transient knock down of Wnt7a
was achieved with a retroviral shRNA system from Open
Biosystems. Proliferation analysis was conducted in B2B cells
using a 6-day cell count, where equal numbers of cells are plated in
six wells and one well is counted each day. In HBEC cells, the Cell
Titer Aqueous assay (Promega) was used and cells were analyzed
every 24 hours for 72 hours. In 1299 cells, a clonogenicity assay
was used, where 1000 cells were plated in normal growth media
and stained with crystal violet for clone growth at day 4. Colonies
were photographed and counted for cloning efficiency. Cloning
efficiency is the number of colonies divided by the number of cells
plated. Three-dimensional basement membrane cultures were
established as previously described [29]. Briefly, 5,000 cells/well
were grown in 2% matrigel (BD Bioscience) with EGF on a 50%
matrigel base layer. For the scratch assay, cells were grown in
complete growth medium until 90–100% confluent. A 3 mm
space was introduced across the diameter of each plate. At time
zero, cells were treated with 1 ug/ml mitomycin to inhibit cell
proliferation. Cell migration was recorded at 24 hours. Images
were captured using a 406lens on a light microscope and a digital
camera.
Transfection
The reporter plasmid PPAR Response Element luciferase
(PPRE) (3 mg), Fzd9 plasmid, and Wnt7a-luciferase were trans-
fected into cells using Lipofectamine Reagent (Invitrogen;
Carlsbad, CA, USA). Cells were collected, washed with PBS,
and resuspended in Luciferase Reporter Lysis Buffer (Promega).
The data are presented as fold-change in relative light units/
milliunits of b-galactosidase and represent the average of three
independent experiments. Modification of the Wnt7a luciferase
was conducted with SssI, HpaII, and HhaI according to the
manufacture’s protocol (New England Biolabs). Transient or stable
transfection of DNMT and Wnt7a shRNA was conducted using
Sure-Silencing shRNA from SABiosciences or retroviral shRNA
from Open Biosystems and Attractene Transfection Reagent
(Qiagen).
Quantitative PCR
RNA was extracted from cells with the AllPrep DNA/RNA
Mini Kit (Qiagen) and 5 mg of RNA was converted to cDNA.
PCR was conducted using SABioscience RT
2 primers and master
mix. GAPDH was used to normalize all samples. The QPCR data
Figure 5. CSC treatment leads to Wnt7a methylation. A) HBEC and B2B cells were treated with 1% CSC in cell growth media for 12 weeks and
Wnt7a expression was measured by QPCR. Error bars are the SE of triplicate experiments. B) Expression of DNMT1 was measured by western blot in
B2B cells treated with 1% CSC for 12 weeks. Loading control is b-actin. C) HBEC and B2B cells treated with 1% CSC for 12 weeks were analyzed for
Wnt7a promoter methylation compared to untreated controls using the Methyl-Profiler system. Error bars are the SE of triplicate experiments.
doi:10.1371/journal.pone.0032921.g005
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vs experimental samples and are the average of at least triplicate
experiments with standard error presented as error bars.
Immunoblot analysis
Cells were harvested and protein extracts were prepared using a
map kinase buffer. Proteins were detected by chemiluminescence
and the ChemiDoc system (BioRad). The following antibodies
were used for immunoblotting: Wnt7A (R&D Systsems), DNMT1
(Abcam) and b-actin (Abcam). b-actin was used as a loading
control.
DNA methylation analysis
DNA was isolated from cell lines and tumor samples using the
AllPrep DNA/RNA Mini Kit (Qiagen) and modified using the EZ
DNA Methylation-Gold kit (Zymo Research). 1 ug of DNA was
used for pyrosequencing for Wnt7a in an assay designed and
conducted by Epigendx. Data from pyrosequencing is presented as
mean percent methylation, which is the mean of the percent
methylation at 13 CpG sites within the CpG island in the Wnt7a
promoter. The Methyl-Profiler system from SABiosciences was
used to measure Wnt7a methylation in 5-aza and CSC treated
cells. Data is presented as percent methylated DNA within the
Wnt7a promoter.
Supporting Information
Figure S1 Expression of Wnt7a is not increased with
DNMT3A or 3B knockdown. QPCR was used to measure
mRNA levels of DNMT3A or 3B and Wnt7a in H1299 cells with
knockdown of DNMT3A or 3B. shRNA data is compared to a
negative control and presented as fold-change normalized to
GAPDH.
(TIF)
Table S1 Methylation of human lung tumor tissue was
analyzed using pyrosequencing. Each tumor was analyzed at
13 CpG sites in the Wnt7a promoter. The percent of tumors
methylated in greater than 0% of the DNA is indicated at the
bottom of the table for each site. Methylation of normal lung tissue
matched to the tumor tissues in Table S1 was analyzed by
pyrosequencing. Each sample was analyzed at 13 CpG sites in the
Wnt7a promoter. The percent of samples with methylation greater
than 0% is indicated at the bottom of the table for each site.
(PDF)
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